Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Lilly invests $3 billion to expand Wisconsin plant
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products. Lilly said Thursday it will expand a Kenosha County,
Eli Lilly CEO says Mounjaro maker may consider other Wisconsin sites for new plants
Fast-growing drugmaker Eli Lilly and Co. would consider Wisconsin sites for new plants beyond a $3 billion project the company announced in Kenosha County, the company’s CEO told the Milwaukee Business Journal.
Eli Lilly to Invest $3B in Wisconsin Plant to Meet Obesity Drug Demand
Eli Lilly LLY recently announced its plans to spend $3 billion to expand the manufacturing facility in Wisconsin that was acquired earlier this year from Nexus Pharmaceuticals. Management expects to start construction on this expansion next year.
Lilly’s Zepbound wins weight loss duel with Novo’s Wegovy
Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.
Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says
Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly.
Zepbound tops Wegovy for weight loss in Eli Lilly study
Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nor
22h
on MSN
Eli Lilly Chief Scientific Officer explains Zepbound's weight loss advantage
Dan Skovronsky, Eli Lilly Chief Scientific Officer, joins 'Fast Money' to talk Zepbound's recent trial results and what it ...
1d
on MSN
Lilly's Zepbound will first be given in the UK to those with 'highest clinical need'
The initial rollout of Eli Lilly's weight loss drug Zepbound in the UK will first go to those with the great clinical need ...
11h
Ozempic cuts drinking, Zepbound beats Wegovy, and a blood test detects 50 cancers: Pharma news roundup
Some patients taking weight-loss drugs, including popular GLP-1 treatments like Ozempic (NVO) and Wegovy, reported reducing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
US adds 227,000 jobs
Drops bid for third term
Federal fraud charges arrest
White Sox legend dies
Massive fire in Baltimore
Trump shows public support
Jury to keep deliberating
‘One Life to Live’ star dies
To be ambassador to China
Biden considers pardons
Hit six months in space
Judge rejects plea deal
Messi wins MLS MVP award
Blackhawks fire coach
Recalls 300K+ Ram trucks
Wild bird lays egg at 74
Ethics report release blocked
Promotes trade w/ Mexico
Meet with lawmakers
'Patriot of the Year' award
Several prisons to be closed
Syrian rebels advance
Pledges hit $100 billion
Appeals court upholds ban
Set to return after 20 years
Iran: Space launch successful
Moon missions delayed
Scott tapped to lead CBP
Joins X Games as CEO
Jury deliberations continue
NBA returning to China
Related topics
Mounjaro
Wegovy
Novo Nordisk
Amgen
Glucagon-like peptide-1
Feedback